검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | ADCT-701 |
Overview Company | National Cancer Institute (NCI) |
Overview Modality | ADC |
Overview Target | Neuroendocrine Carcinomas |
Overview Indication | Neuroendocrine Carcinomas; Neuroendocrine Tumors |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Mechanism | ADC payload and chemotherapy sensitivity through NOTCH1-mediated transdifferentiation |
PK/PD Animal (cat.) | In vitro |
PK/PD Experiment | In ACC, ADCT-701, a DLK1 targeting antibody-drug conjugate (ADC), shows in vitro and in vivo activity but is overall limited due to high expression and activity of the drug efflux protein ABCB1 (MDR1, P-glycoprotein). |
Toxicology Animal (cat.) | In vitro |
Toxicology Major finding | A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma.. Cancer immunotherapies produce remarkable results in B cell malignancies; however, optimal cell surface targets for many solid cancers remain elusive. Here, we present an integrative proteomic, transcriptomic, and epigenomic analysis of tumor and normal tissues to identify biologically relevant cell … |
Clinical Data Tier / Score | A · 6 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | ADCT-701 |
Overview Company | National Cancer Institute (NCI) |
Overview Modality | ADC |
Overview Target | Neuroendocrine Carcinomas |
Overview Indication | Neuroendocrine Carcinomas; Neuroendocrine Tumors |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Mechanism | ADC payload and chemotherapy sensitivity through NOTCH1-mediated transdifferentiation |
PK/PD Animal (cat.) | In vitro |
PK/PD Experiment | In ACC, ADCT-701, a DLK1 targeting antibody-drug conjugate (ADC), shows in vitro and in vivo activity but is overall limited due to high expression and activity of the drug efflux protein ABCB1 (MDR1, P-glycoprotein). |
Toxicology Animal (cat.) | In vitro |
Toxicology Major finding | A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma.. Cancer immunotherapies produce remarkable results in B cell malignancies; however, optimal cell surface targets for many solid cancers remain elusive. Here, we present an integrative proteomic, transcriptomic, and epigenomic analysis of tumor and normal tissues to identify biologically relevant cell … |
Clinical Data Tier / Score | A · 6 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교